Filings monitor · LH

What LABCORP HOLDINGS INC.'s SEC filings said

10-Q for 2026Q3, filed 30 Oct 2026. Each line is something a filing stated, ranked by score and linked to its source.

Ranked highest

1. Guidance / Outlook74 · importance in its document · 8-K exhibit · 28 Oct 2026
   Labcorp raised its 2026 enterprise revenue growth guidance to 5.9%–6.7%, from 5.4%–6.3%, and adjusted EPS guidance to $18.30–$18.70, from $18.10–$18.55. Updated revenue guidance is $14.779–$14.887 billion for the enterprise,…
2. Acquisition / Partnership / Divestiture65 · importance in its document · 10-Q · 2026Q3
   On June 28, 2026, Labcorp agreed to acquire select assets of an outreach laboratory services business for approximately $155.0 million, subject to customary closing conditions and approvals. On October 15, it announced an agreement to…
3. Guidance raised60 · rule score among filings · 8-K Item 2.02 · 28 Oct 2026
   Raises Full Year 2026 Guidance
4. Liquidity and Debt Position56 · importance in its document · 10-Q · 2026Q3
   At September 30, 2026, Labcorp held $261.8 million of cash and had $1,000.0 million available under its revolving credit facility, which expires in 2030. Nine-month operating cash flow increased $174.5 million year over year to $1,200.8…
5. Restructuring and Headcount53 · importance in its document · 10-Q · 2026Q3
   Net restructuring and other charges increased to $15.9 million in the third quarter of 2026 from $5.9 million in the prior-year quarter. The 2026 quarter included $12.3 million of severance and other personnel costs, $2.5 million of…

Ranked by score, 0–100. A topic read from a document carries its importance within that document; an 8-K event carries the rule score that ranks a filing among filings. Neither is about the share price, and the two scales are named on each row because they are not the same measure.

Latest report: 10-Q · 2026Q3 filed 30 Oct 2026

Full report · Filing on EDGAR

• Acquisition / Partnership / DivestitureImportance 65
  On June 28, 2026, Labcorp agreed to acquire select assets of an outreach laboratory services business for approximately $155.0 million, subject to customary closing conditions and approvals. On October 15, it announced…
• Liquidity and Debt PositionImportance 56
  At September 30, 2026, Labcorp held $261.8 million of cash and had $1,000.0 million available under its revolving credit facility, which expires in 2030. Nine-month operating cash flow increased $174.5 million year…
• Restructuring and HeadcountImportance 53
  Net restructuring and other charges increased to $15.9 million in the third quarter of 2026 from $5.9 million in the prior-year quarter. The 2026 quarter included $12.3 million of severance and other personnel costs,…
• Capital Return ProgramImportance 52
  On July 8, 2026, the board authorized an additional $1,000.0 million of common-stock repurchases, bringing remaining authorization to $1,378.6 million at September 30, with no expiration date. Common-stock repurchases…
• Capital ExpendituresImportance 51
  Capital expenditures were $404.2 million for the nine months ended September 30, 2026, up from $310.6 million in the comparable 2025 period. The 2026 expenditure was 3.6% of revenue and supported core-business growth,…
• Equity Method LossesImportance 45
  Equity method loss, net, increased 109.3% to $11.0 million in the third quarter of 2026 from $5.2 million in the prior-year quarter. For the first nine months, the loss increased 207.3% to $22.3 million from $7.2…
• Operating Income and MarginsImportance 45
  Third-quarter operating income increased 1.4% to $402.1 million, while segment operating income rose 11.7% to $650.6 million. Dx operating income increased 9.2% to $491.6 million and its margin expanded 40 basis points…
• Revenue Performance and MixImportance 43
  For the three months ended September 30, 2026, revenue was $3,810.0 million, up 6.9% year over year; nine-month revenue was $11,078.7 million, up 6.2%. Third-quarter growth included 5.5% organic revenue growth and a…
• End-Market Demand TrendsImportance 43
  For the three months ended September 30, 2026, Labcorp’s revenue increased 6.9% year over year, driven by 5.5% organic growth. Diagnostics (Dx) revenue grew 6.5%, with requisition volume up 4.8% and price/mix up 1.7%;…
• FX / Currency ImpactImportance 38
  For the nine months ended September 30, 2026, Labcorp recognized $13.1 million of foreign currency transaction losses, compared with $8.0 million in the corresponding 2025 period, an increase of approximately 64%.…
• Interest Rate and Refinancing ExposureImportance 38
  The Company’s 2026 Term Loan, accounts receivable facility, and revolving credit facility bear variable interest rates. Labcorp states that higher benchmark rates would further increase interest expense on…
• Income Tax Rate ChangesImportance 30
  The effective tax rate fell to 19.8% in the third quarter of 2026 from 22.4% in the third quarter of 2025, while income tax provision declined to $64.9 million from $75.5 million. The company attributed the quarterly…

8-K filings last 12 months

• Guidance raised28 Oct 2026 · 8-K Item 2.02 · Flagged · rule score 60
  “Raises Full Year 2026 Guidance”
  Read from the attached exhibit: Guidance / Outlook · Operating Cash Flow Trends · Capital Expenditures
• Press release attached to an 8-K21 Oct 2026 · 8-K
  Read from the attached exhibit: Quarterly Dividend Declaration
• Press release attached to an 8-K10 Sept 2026 · 8-K
  Read from the attached exhibit: Guidance / Outlook
• Other officer change14 Aug 2026 · 8-K Item 5.02 · Routine · rule score 15
  “On August 11, 2026, Megan D. Bailey notified Labcorp Holdings Inc. (the “Company”) of her decision to resign as Executive Vice President and President, Central Laboratories and International of the Company, effective September 4, 2026.”
• Results (release not read)30 Jul 2026 · 8-K Item 2.02 · Routine · rule score 20
• Results (release not read)30 Apr 2026 · 8-K Item 2.02 · Routine · rule score 20
• New debt20 Mar 2026 · 8-K Items 1.01, 2.03 · Routine · rule score 25
• Results (release not read)17 Feb 2026 · 8-K Item 2.02 · Routine · rule score 20
• Management change (filing not read)9 Feb 2026 · 8-K Item 5.02 · Routine · rule score 20
• New debt29 Jan 2026 · 8-K Items 1.01, 2.03 · Routine · rule score 25
• Management change (filing not read)15 Dec 2025 · 8-K Item 5.02 · Routine · rule score 20
• Board change10 Dec 2025 · 8-K Item 5.02 · Routine · rule score 10
  “On December 5, 2025, Dr. D. Gary Gilliland notified the Board of Directors (the “Board”) of Labcorp Holdings Inc. (the “Company”) of his decision to retire from the Board, effective December 31, 2025.”
• Management change (filing not read)24 Nov 2025 · 8-K Item 5.02 · Routine · rule score 20

Earlier reports

• 10-Q · 2026Q2filed 5 Aug 2026
  Liquidity and Debt Position · Capital Return Program · Interest Rate and Refinancing Exposure

Topics are read from the text of the 10-K, 10-Q or the exhibit attached to an 8-K, each linked to the passage it came from. 8-K events are labelled by fixed rules from the item codes and the filing text — the same rules for every company and every year. The Full Picture merges these with earnings calls and news.